Treasury’s initiative to reduce M&A motivated by tax avoidance could leave Pfizer in a lurch, without an attractive acquisition target to reenergize the big pharma’s long-term outlook. Other deals hang in the balance, most notably AbbVie’s $53.3 billion acquisition of Shire, already signed but not yet closed.
U.S. tax policy changes intended to reduce the economic advantage from mergers and acquisitions done for tax inversion leave Pfizer Inc. investors wondering what the changes will mean for the firm’s M&A strategy, particularly whether a potential mega-merger with AstraZeneca PLC will be off the table.
Other pharma deals hang in the balance, most notably AbbVie Inc.’s $53.3 billion acquisition of Shire PLC, already signed but not yet closed [See Deal]. The...
Two pharmacies, a medical spa and a telehealth company voluntarily removed efficacy, safety and quality claims for compounded GLP-1 products after innovator companies filed challenges with the National Advertising Division.
Health and Human Services Secretary Robert F. Kennedy Jr. said a policy that would remove the tax write-off for pharma advertising expenses would be coming in a few weeks.
Webpages, a healthcare professional pamphlet and a medical conference exhibit booth panel make unsupported comparative superiority claims about generic torsemide products and misrepresent risks, the Office of Prescription Drug Promotion says in its first warning letter of 2025.
A professional slide deck for the drospirenone/estetrol oral contraceptive inappropriately suggests it is safer than other estrogen-containing products and understates risks, Office of Prescription Drug Promotion said in the first “untitled” letter issued since reductions-in-force.
President Trump’s new Executive Order on drug pricing reprises several policy themes from his first administration, including giving the FDA many tasks intended to increase competition in the marketplace.
Health and Human Services Secretary Robert F. Kennedy Jr. said a policy that would remove the tax write-off for pharma advertising expenses would be coming in a few weeks.
Webpages, a healthcare professional pamphlet and a medical conference exhibit booth panel make unsupported comparative superiority claims about generic torsemide products and misrepresent risks, the Office of Prescription Drug Promotion says in its first warning letter of 2025.
